After at least 85 patients per arm had completed four weeks of therapy, each eluxadoline arm was evaluated for efficacy by an outside source. At this time, randomization to the 5 mg arm was discontinued due to lack of efficacy. New patients were then randomized (1:1:1:1) to the remaining eluxadoline arms or placebo. 8 IBS-D involves abnormally increased GI motility and secretions, leading to stool urgency and abdominal pain. 2 Altering the function of these opioid receptors may improve symptoms and help regulate colon function. 8 This article will discuss the use of eluxadoline in patients with IBS-D.